Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 6
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2022-02-12T01:02:18-05:00",
  "meta" : {
    "versionId" : "51",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "TJC EH Steward",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: The purpose of this value set is to represent concepts for medications of oral factor Xa inhibitors indicated for venous thromboembolism (VTE) prophylaxis and treatment.),(Data Element Scope: This value set may use a model element related to Medication.),(Inclusion Criteria: Includes concepts that represent a medication for oral forms of factor Xa inhibitors.),(Exclusion Criteria: Excludes concepts that represent dose forms of factor Xa inhibitors other than oral.)",
  "name" : "OralFactorXaInhibitorForVTEProphylaxisOrVTETreatment",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1364435",
      "display" : "apixaban 2.5 MG Oral Tablet",
      "version" : "11042024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1364445",
      "display" : "apixaban 5 MG Oral Tablet",
      "version" : "11042024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1599543",
      "display" : "edoxaban 15 MG Oral Tablet",
      "version" : "11042024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1599551",
      "display" : "edoxaban 30 MG Oral Tablet",
      "version" : "11042024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1599555",
      "display" : "edoxaban 60 MG Oral Tablet",
      "version" : "11042024"
    }, {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "code" : "1992427",
      "display" : "{74 (apixaban 5 MG Oral Tablet) } Pack",
      "version" : "11042024"
    } ],
    "total" : 6,
    "identifier" : "urn:uuid:ef2626ab-9d32-4496-be92-c454c8e47de0",
    "timestamp" : "2024-12-10T10:00:52-05:00"
  },
  "title" : "Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment",
  "extension" : [ {
    "valueContactDetail" : {
      "name" : "TJC EH Author"
    },
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueString" : "VTE-01,VTE-02",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-keyWord"
  }, {
    "valueDate" : "2024-01-31",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2022-02-12",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "active",
  "id" : "097533f3-288f-4cad-9bd5-32a5d79acf08",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.117.1.7.1.134"
  } ],
  "version" : "20220212"
}